Is magnesium worth drawing at baseline before starting liraglutide?

Setup, so nobody has to ask: magnesium · liraglutide.

I want to decide this in advance so that I am not deciding it under pressure later.

Assume I will follow the plan I write down, so I would like it to be a good one.

How would you structure this, and what thresholds would you set in advance?

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

More usefully, haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

The relevant detail is that this is answerable, and the answer is mostly about which tests rather than how many.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Research-use compounds are not approved for human use, and no panel makes that safer.

Decide the action for each result before you order the test.